Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease.

ABSTRACT: Amyloid-β (Aβ) positron emission tomography (PET) imaging and cerebrospinal fluid (CSF) biomarkers are now established tools in the diagnostic workup of patients with Alzheimer's disease (AD), and their use is anticipated to increase with the introduction of new disease-modifying therapies. Although these biomarkers are comparable alternatives in research settings to determine Aβ status, biomarker testing in clinical practice requires careful consideration of the strengths and limitations of each modality, as well as the specific clinical context, to identify which test is best suited for each patient. This article provides a comprehensive review of the pathologic processes reflected by Aβ-PET and CSF biomarkers, their performance, and their current and future applications and contexts of

SUBMITTER: Leuzy A 

PROVIDER: S-EPMC11881640 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature